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Abstract
Background: There is a lack of head-to-head studies com-
paring the efficacy of fingolimod (FIN) and natalizumab 
(NTZ) as second-line therapy for relapsing-remitting multi-
ple sclerosis (RRMS). Methods: Multicenter, observational 
study, in which, information of 388 patients randomly select-
ed and treated with FIN or NTZ in routine clinical practice 
was retrospectively collected with the main objective of 
comparing the annualized relapse rate (ARR) over the first 
year, after FIN or NTZ treatment initiation. Results: Mean ARR 
during the first year of treatment was 0.28 in FIN group and 
0.12 in NTZ group (p = 0.0064); nevertheless, the difference 
between groups lost statistical significance when the pro-
pensity score analysis was performed. Time to disability 
 progression was similar in both treatment groups (12.3 ± 
6.7 months in FIN, and 12.8 ± 0.1 months in NTZ; p = 0.4654). 
Treatment persistence after the first year of treatment was 
higher in patients treated with FIN (95%) than in those treat-
ed with NTZ (84%; p = 0.0014). Conclusions: After 12 months 
of treatment, both FIN and NTZ reduced the ARR, but ARR 
percent reduction was significantly higher with NTZ. Treat-
ment persistence was higher in patients receiving FIN.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, 
demyelinating, and neurodegenerative disease that af-
fects the central nervous system. The cause of MS is un-
known, but it is thought to be an immune-mediated dis-
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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ease [1, 2]. Relapsing-remitting MS (RRMS) is charac-
terized by clearly defined relapses of new or increasing 
neurologic symptoms. These relapses are followed by 
periods of partial or complete recovery (remissions) [3, 
4]. Most patients start with a relapsing-remitting course, 
which may be followed by a secondary progressive 
phase. A minority of subjects present with an insidious 
progression of disability from onset, or primary pro-
gressive [5]. Current first-line disease-modifying thera-
pies (DMT), interferon beta and glatiramer acetate, are 
partially effective for the treatment of RRMS. Treatment 
strategies for patients with suboptimal response to a 
first-line DMT include the escalation to a more effica-
cious DMT, fingolimod (FIN; a sphingosine 1-phopahte 
receptor modulator), or natalizumab (NTZ; an α4-
integrin monoclonal antibody) [6]. Until present, there 
are no head-to-head randomized clinical trials that have 
compared the clinical efficacy of FIN and NTZ in pa-
tients with RRMS nonresponding to first-line DMT; 
nevertheless, NTZ is perceived as more efficacious drug 
than FIN, perception that has not been proved neither 
in clinical research nor in clinical practice. Factors that 
may have contributed to this perception are (i) NTZ was 
first marketed and was used as the only second-line 
DMT for several years and (ii) the subsequent market-
ing authorization of FIN relegated this drug to the treat-
ment of patients that failed a previous therapy with NTZ 
or had an increased risk of developing progressive mul-
tifocal leukoencephalopathy. In addition, MS relapses 
have been observed in 30–40% of the patients after 
switching from NTZ to FIN [7–9]. 
The objective of this study was to compare the effective-
ness of FIN versus NTZ administered in routine clinical 
practice as a second-line therapy, in patients with RRMS.
Materials and Methods
This was a national, multicenter, retrospective with random-
ized patient selection, observational study carried out in Spain. 
The information of patients aged 18–55 years, with MS diagnosed 
according to 2010 McDonald criteria [10], a relapsing-remitting 
course [4], and treated with FIN or NTZ between November 2011 
and April 2013 with, at least, 12 months of follow-up, was retro-
spectively collected from their medical records at 33 hospital out-
patient Neurology Services with medical activity dedicated to pa-
tients with RRMS. FIN and NTZ were prescribed in accordance 
with the local marketing authorization. Exclusion criteria included 
a clinical course different to RRMS; prior treatment with FIN, 
NTZ, immunoglobulins, cyclophosphamide, cladribine, mitoxan-
trone, and/or monoclonal antibodies at any moment; and treat-
ment with immunosuppressants or investigational DMT within 
the 12 months prior to FIN or NTZ initiation. Naïve patients 
whose first DMT was FIN or NTZ for rapidly evolving severe 
RRMS were also excluded [11]. To minimize potential selection 
bias, patients that fulfilled all eligibility criteria were randomly se-
lected in each center.
The study was conducted in accordance with ethical principles 
that have their origin in the Declaration of Helsinki. The study was 
approved by the Spanish Agency of Medicines and Medical Devices, 
and the Ethics Committees of Hospital Infanta Cristina, Hospital de 
Bellvitge, Hospital de Navarra, and Hospital Virgen de la Arrixaca.
The primary endpoint of the study was the difference between 
treatments in the annualized relapse rate (ARR) over the first 
year, after FIN or NTZ treatment initiation. Secondary endpoints 
included the number of relapses, time to first relapse, proportion 
of relapse-free patients, proportion of patients with confirmed 
disability progression (increase of ≥1.5 points on the Expanded 
Disability Status Scale (EDSS) score from a baseline score of < 1, 
or increase ≥1 point from a baseline score ≥1, confirmed after, at 
least, 3 months), number of T1 Gd-enhancing lesions, propor-
tion of patients free of T1 Gd-enhancing lesions, proportion of 
patients free of new or enlarging T2-hyperintense lesions, pro-
portion of patients free of radiologic activity (defined as the ab-
sence of T1 Gd-enhancing lesions and new or increased T2 le-
sions), proportion of patients free of clinical activity (defined as 
the absence of relapses and sustained disability progression), pro-
portion of patients free of disease (defined as the absence of clin-
ical and radiologic activity), number of adverse events (AE) dur-
ing the observation of the first dose administered, number of AEs 
after treatment initiation, and proportion of patients that inter-
rupted the study within the first year after 2nd-line treatment 
initiation.
Statistical Analysis
The primary endpoint of the study was the ARR over the first 
year, after FIN or NTZ treatment initiation. An analysis of covari-
ance was used to assess the percent change on the ARR adjusting 
for the EDSS score as it was the only variable that showed a sig-
nificant difference at baseline. In addition, to define comparable 
groups to assess the ARR, a propensity score (PS) analysis match-
ing 1: 1 was performed. Patients were PS matched on age, EDSS 
score, number of T1 Gd-enhancing lesions, and number of T2 le-
sions when starting on 2nd-line therapy, ARR (over the previous 
year), and time passed since RRMS diagnosis. 
Continuous variables are presented as means, standard devia-
tions, and 95% CI, as appropriate. Categorical variables are report-
ed by using frequencies and percentages. 
Descriptive statistics were calculated for demographic and clin-
ical characteristics.
The number of relapses was analyzed with the Mann-Whitney 
U test. Kaplan-Meier was used to assess the time to first relapse 
since treatment initiation and the time to disability progression. 
Comparisons between groups regarding the percentage of patients 
free of clinical activity, disease, or radiologic activity, and the per-
centage of patients that discontinued the study were assessed using 
the chi-square or Fisher exact test. Comparison between groups 
regarding the number of lesions observed in MRI was assessed us-
ing the Wilcoxon signed-rank test.
A 2-tailed p value < 0.05 was used to denote statistically signifi-
cant differences.
All statistical analyses were performed with SAS® software ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA).
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Results
The study included 388 patients; of them, 74 (19.1%) 
were excluded from the analysis, 33 (8.5%) due to lack of 
information regarding the primary endpoint (AAR), 32 
(8.2%) for not fulfilling the eligibility criteria, and 9 (2.4%) 
for other reasons. Thus, 314 (80.9%) patients were evalu-
able. A reduced population of 260 patients (130 patients 
per group) was obtained after the PS matching 1: 1 used 
for the additional analysis of the ARR.
Out of the 314 evaluable patients, 184 (58.6%) patients 
were treated with FIN and 130 (41.4%) with NTZ. Clini-
cal and demographic characteristics of both groups at the 
2nd-line treatment initiation were similar, only a statisti-
cally significant difference was found in the mean EDSS 
score (2.65 ± 1.42 in FIN group versus 3.08 ± 1.56 in NTZ 
group, p = 0.0147; Table 1). 
Considering the whole study population, and com-
pared with the previous year, during the first year of treat-
ment, the ARR showed a statistically significant reduction 
in both patient groups, from 1.67 ± 0.98 to 0.28 ± 0.62 in 
FIN group (p < 0.0001) and from 1.71 ± 1.37 to 0.12 ± 0.33 
in NTZ group (p < 0.0001). Nevertheless, the ARR during 
the first year of treatment with the study drugs was sig-
nificantly lower in NTZ group (p = 0.0064). Differences 
between groups in the ARR mean percent change were 
only statistically significant during the first year of treat-
ment (Fig. 1). Very similar results were found when the 
PS was used to, additionally, analyze the ARR. Neverthe-
less, with the PS analysis, the difference between groups 
in the ARR mean percent change observed in the first 
year lost the statistical significance (–83.5% [95% CI –90.2 
to –76.7] in FIN group versus –92.3% [95% CI –96.2 
to –88.3] in NTZ group, [p = 0.0958]). 
The mean number of relapses during the first year of 
treatment was higher in FIN group (0.28 ± 0.62) than in 
the group of patients treated with NTZ (0.12 ± 0.33; p = 
0.0237). After the first year, the mean number of relapses 
in both groups was similar (0.15 ± 0.42 vs. 0.12 ± 0.34 dur-
ing the 2nd year, in FIN group versus NTZ group, respec-
tively [p = 0.5211]; and 0.10 ± 0.38 vs. 0.10 ± 0.33 during 
the 3rd year in FIN vs. NTZ group, respectively [p = 
0.8001]). 
The cumulative probability of remaining free of re-
lapse was higher in NTZ group (61.5% in FIN group and 
71.5% in NTZ group, at 48 months [HR 1.56; 95% CI 
1.00–2.42; p = 0.0450]; Fig. 2). Considering only the pa-
tients that relapsed, no statistically significant differences 
Table 1. Clinic-demographic characteristics of the patients at baseline (2nd-line treatment initiation)
Variable FIN (n = 184) NTZ (n = 130) p value
Age, years, mean ± SD 37.8±7.8 38.4±7.7 0.4421
Gender, female, n (%) 130 (70.6) 88 (67.7) 0.5750
Time since first MS symptom until RRMS diagnosis, months, mean ± SD 22.2±33.3 19.0±26.7 0.4623
Time since RRMS diagnosis until 2nd-line treatment, years, mean ± SD 7.06±5.56 7.01±5.17 0.8110
Time since RRMS diagnosis until the last relapse prior to the 2nd-line treatment,
years, mean ± SD 6.67±5.55 6.67±5.17 0.7305
No. of relapses within the year prior to the 2nd-line treatment, mean ± SD 1.64±0.91 1.56±0.77 0.4898
No. of disease modifying therapies prior to the 2nd-line treatment, mean ± SD 1.47±0.66 1.42±0.64 0.4124
Patients with comorbidities at the time of 2nd-line treatment initiation, n (%) 42 (22.8) 32 (24.6) 0.7224
ARR in previous year, mean ± SD 1.67±0.98 1.71±1.37 0.7129
EDSS, mean ± SD 2.65±1.42 3.08±1.56 0.0147
No. of T1 gadolinium-enhancing lesions, mean ± SD1 1.45±3.30 1.37±2.20 0.4574














1 Only in patients with MRI available. For this variable, no. of evaluable patients = 121 for FIN group and n = 106 for NTZ group.
2 Only in patients with MRI available. For this variable, no. of evaluable patients = 125 for FIN group and n = 110 for NTZ group.
FIN, fingolimod; NTZ, natalizumab; SD, standard deviation; MS, multiple sclerosis; RRMS, relapsing-remitting MS; ARR, annualized 
relapse rate; EDSS, Expanded Disability Status Scale.
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were found in the mean time to first relapse since 2nd-line 
treatment initiation (10.8 months [95% CI 8.6–13.1] in 
FIN group, and 13.5 months [95% CI 9.7–17.4] in NTZ 
group [p = 0.3137]).
Compared to baseline, 12 months after 2nd-line treat-
ment initiation, the EDSS mean percent reduction was 
similar in both groups (–8.86% [95% CI –14.01 to –3.71] 
and –8.88% [95% CI –17.29 to –0.46] in FIN  and NTZ 
group, respectively [p = 0.1628]). 
No statistically significant differences were found in 
confirmed disability progression at month 12 after 2nd-
line treatment initiation (6.5% of the patients in FIN 
group, and 4.6% in NTZ group; p = 0.7944). The propor-
tion of patients showing confirmed disability progression 
at month 24 was 12.6 and 8.1% in FIN group and NTZ 
group, respectively (p = 0.3248; Fig. 3). Mean time to dis-
ability progression was 12.3 ± 6.7 months in FIN group 
and 12.8 ± 0.1 months in NTZ group (p = 0.4654).
Table 2 shows the radiologic activity assessed in a sub-
group of 95 patients (49 FIN and 46 NTZ) with MRI avail-
able at the beginning of the 2nd-line treatment initiation 
and annual MRIs throughout the study. Twelve months 
after 2nd-line treatment initiation, results from the anal-
ysis of the number of T1 gadolinium-enhancing lesions, 
the proportion of patients free of T1 Gd-enhancing le-
sions, and the proportion of patients free of new or en-
larging T2-hyperintense lesions favored NTZ. At month 
24, differences between treatment groups lost statistical 
significance. 
No statistically significant differences were found in 
the proportion of patients free of clinical activity after 
12 months of treatment with the 2nd-line drugs (73.1% 
in FIN group and 82.4% in NTZ group; p = 0.1140). Con-
sidering patients with continued treatment and MRI val-
id for assessment at month 12 (n = 149), the proportion 
of patients free of radiologic activity was 63.5% in FIN 
group and 96.0% in NTZ group (p < 0.0001), and the pro-
portion of patients free of disease was 50.0% in FIN group 
and 78.7% in NTZ group (p = 0.0002).
Table 3 summarizes the AEs reported over the obser-
vation period for the first dose of the 2nd-line treatment 
and those reported afterward throughout the study. In-
fection was the most common AE in each group; never-
theless, its incidence was lower in FIN group (23.6%) than 
in NTZ group (57.1%; p = 0.0005). 
During the first year on 2nd-line therapy, 1.1% of the 
patients in FIN interrupted the treatment permanently and 
5.4% temporarily; whereas in the NTZ group, 1.4% inter-
rupted the treatment permanently and 2.3% temporarily. 
AEs were the most common reasons for temporary inter-
ruptions (in 5.4% of FIN patients and in 1.5% of NTZ pa-
tients). The most common reasons for permanent inter-
ruptions were lack of effectiveness and patient decision in 























81.8%* 89.9%† 91.6%‡ 92.3%* 91.0%† 92.9%‡
n = 184 n = 184 n = 184 n = 120 n = 130 n = 130 n = 130 n = 105
FIN NTZ
* p = 0.0320
† p = 0.8275
‡ p = 0.6350
Fig. 1. ARR according to treatment group (total study population). *, †, ‡ p value for percent change comparison 
between treatment groups regarding the year of follow-up (* year 1, † year 2, and ‡ year 3). FIN, fingolimod; NTZ, 
natalizumab; ARR, annualized relapse rate.
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Fig. 3. Proportion of patients with confirmed disability progres-
sion after 12 and 24 months of 2nd-line treatment initiation. Con-
firmed disability progression was defined as an increase of 
≥1.5 points on the EDSS score from a baseline score of < 1, or an 
increase ≥1 point from a baseline score ≥1, confirmed after, at 
least, 3 months. As the EDSS score is assessed at 3, 6, and 12 months 
during the first year of follow-up, if disease progression was ob-
served at month 3, confirmation was assessed at month 6; if disease 
progression was observed at month 6, confirmation was assessed 
at month 12; and if disease progression was observed at month 12, 
confirmation was assessed at month 18. * When disease progres-
sion was observed at month 12, but EDSS score was not available 
afterwards to assess confirmation. FIN, fingolimod; NTZ, natali-
zumab.
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Table 2. MRI activity at baseline (2nd-line treatment initiation), 12 and 24 months, according treatment group
Variable FIN (n = 49) NTZ (n = 46) p value



































Change in the number of T1 gadolinium-enhancing lesions at
12 months2, mean ± SD –0.92±3.25 –1.46±2.35 0.0512
Percent change in the number of T1 gadolinium-enhancing
lesions at 12 months2, 3 (95% CI) –64.3 (–100.2 to –28.5) –95.6 (–104.7 to –86.6) 0.0809
1 For these variables, no. of evaluable patients = 20 for FIN group and n = 36 for NTZ group.
2 Compared to baseline.
3 For this variable, no. of evaluable patients = 23 in both groups.
FIN, fingolimod; NTZ, natalizumab.
Table 3. Adverse events
FIN (n = 184), n (%) NTZ (n = 130), n (%)
AEs reported over the observation period for the first dose of the 2nd-line treatment1
Patients with, at least, one AE 2 (1.1) 5 (3.8)
Total number of AEs2 2 6
Infusion reaction 0 (0.0) 2 (33.3)
First-degree atrioventricular block 1 (50.0) 0 (0.0)
Other 1 (50.0) 4 (66.7)
AEs reported throughout the study, since 2nd-line treatment initiation3
Patients with, at least, one AE 41 (22.8) 20 (15.4)
Total number of AEs2, 4 55 49
Infection 13 (23.6) 28 (57.1)
Increased liver enzymes 7 (12.7) 2 (4.1)
Lymphopenia (<200 lymphocytes/μL) 3 (5.4) 0 (0.0)
Infusion reaction 0 (0.0) 2 (4.1)
Symptomatic bradycardia 0 (0.0) 1 (2.0)
Macular edema 2 (3.6) 0 (0.0)
Immune reconstitution inflammatory syndrome 1 (1.8) 0 (0.0)
Other 30 (54.5) 16 (32.6)
More than one AE could be reported by the same patient.
1 AEs reported the same day or the day after the first dose administration (at the beginning of the treatment or once the treatment 
had been reintroduced after a temporal treatment interruption).
2 Percentages calculated over the total number of AEs in each group. 
3 AEs reported over the observation period for the first dose have been excluded.
4 Differences between groups not statistically significant, except for “Infection” (p = 0.0005) and “Other” (p = 0.0248).
AEs, adverse events; FIN, fingolimod; NTZ, natalizumab.
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for the John Cunningham virus in NTZ group (1.5%). 
Mean time of treatment interruption was 1.82 ± 0.90 months 
in FIN group and 2.60 ± 1.35 months in NTZ group. 
Treatment persistence after the first year was higher in 
patients treated with FIN (94.6 vs. 83.9% in NTZ; p = 
0.0014). 
Discussion/Conclusion
In this retrospective, observational study, we com-
pared the effectiveness of FIN and NTZ in RRMS patients 
failing on a first-line therapy in clinical practice in Spain. 
The clinical and demographic characteristics of the pa-
tients were similar in both treatment groups at the time 
of 2nd-line therapy initiation; only EDSS score was sig-
nificantly higher in NTZ group. Over the first year of 
treatment, and compared with baseline, both FIN and 
NTZ reduced significantly the ARR. Considering the 
whole study population, we found a significant higher 
percent reduction in patients treated with NTZ during 
the first year, but differences lost the statistical signifi-
cance at the 2nd and 3rd year. As EDSS score was higher 
in NTZ at the beginning of the 2nd-line therapy, and 
treatment response can be influenced by the disease activ-
ity [12], the 2 patient groups analyzed could have not 
been comparable. To avoid this potential bias, the PS was 
used to analyze the ARR and, as a result, no statistically 
significant differences were found at any time-point. In 
any case, this finding should be considered with caution, 
as the loss of the statistical significance may be attribut-
able to the lower number of patients included in the anal-
ysis after being matched. Reviewing other noninterven-
tional studies, we found contradictory results; some stud-
ies [13–15] showed higher reduction in ARR with NTZ 
when compared to FIN, but others showed no differences 
between both drugs [16, 17]. In line with our results, in 2 
[13, 15] of the 3 studies where differences favored NTZ 
analyzing the whole study population, these differences 
disappeared when PS was applied. 
As already observed in 4 noninterventional studies 
[14, 18–20], in our study, after 2 years of treatment, the 
probability of remaining free of relapse was higher in 
NTZ group than in FIN group. In contrast, no significant 
differences between treatment groups in the proportion 
of patients free of relapses have been observed in another 
5 noninterventional studies [13, 15–17, 21]. 
We found differences favoring NTZ in the EDSS scores 
at month 12. This is in line with the study of Kalincik et 
al. [14] in which a higher proportion of patients treated 
with NTZ, compared with those treated with FIN, expe-
rienced 6-month sustained regression disability. Lanzillo 
et al. [15] also found a change in EDSS after 2 years of 
therapy favoring NTZ, but statistical significance disap-
peared when adjusting for the PS. On the contrary, Bar-
oncini et al. [18] found, in unmatched population, a high-
er risk for EDSS worsening in patients treated with NTZ 
but, when adjusting for PS, a trend favoring NTZ was 
found. In other studies [13, 16, 17, 20, 22], no differences 
were found between FIN and NTZ in the evolution of the 
EDSS score. 
After 1 and 2 years of follow-up, 3 studies found a low-
er proportion of MRI-active patients in NTZ, when com-
pared to FIN [18, 19, 22]. Conversely, Gajoffato et al. [22] 
did not find differences between the 2 drugs on MRI out-
comes after a mean of 13 months of follow-up. In our 
study, higher improvements in MRI outcomes were seen 
at month 12 in NTZ. Nevertheless, differences at 
24 months were not statistically significant. 
Both, FIN and NTZ, were well tolerated, and the AEs 
reported by the participants in our study are consistent 
with the safety information from randomized clinical tri-
als [23, 24]. Notably, the incidence of infections was high-
er in NTZ. Few patients from both treatment groups dis-
continued the study due to AEs; nevertheless, persistence 
after the first year was higher in patients that were started 
on FIN than in those that started on NTZ. Probably this 
was a consequence of NTZ discontinuation due to safety 
concerns as the risk of progressive multifocal leukoen-
cephalopathy associated with the use of NTZ is well 
known [25, 26]. In line with our results, higher rates of 
discontinuations in patients receiving NTZ have also seen 
by Gajofatto et al. [22] and Guger et al. [13]. Contrarily, 
Frisell et al. [27] found higher proportion of patients re-
maining on NTZ than on FIN but differences in discon-
tinuation rates between FIN y NTZ disappeared when a 
covariate-adjusted analysis was applied. 
Focusing on the group of patients treated with FIN, the 
results obtained in our study were very similar to those 
found in a large cohort of Spanish patients (n = 211) in 
which the effectiveness and safety of FIN for the treat-
ment of RRMS were also retrospectively assessed [28]. In 
that cohort, the ARR after 24 months of treatment with 
FIN was 0.3, compared to an ARR of 0.16 observed in our 
study after 24 months of treatment. The proportion of 
relapse-free patients at month 36 was 62%, compared 
with 61.5% at month 48 in our study, and the percentage 
of patients with confirmed disability progression at 
month 12 was 6.9%, compared to 6.5% in our study. Dif-
ferently from our study population, 20.4% of the patients 
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in that cohort were previously treated with NTZ, and 
20.8% were treatment-naïve patients. Despite the differ-
ences between the 2 populations, the similarity of the re-
sults obtained gives us a clear idea of what FIN, adminis-
tered in real-life clinical practice, can offer.
As in other observational studies, our main limitation 
was the potential patient selection bias. To minimize this 
bias, patients were randomly selected from those that ful-
filled the inclusion and exclusion criteria in each of the 
participant sites. Another potential source of bias is the 
selection of the treatment that, in routine clinical practice, 
can be influenced by the patient’s profile and/or the phy-
sician’s preference. Despite this, we found that only the 
EDSS score differed significantly at baseline. When PS 
matching 1: 1 was used to control confounding covariates 
that could have an effect in the analysis of our main end-
point (ARR), the number of patients was reduced and, in 
consequence, the statistical power for this analysis. An-
other limitation was that MRI data at 24 months were 
only available in a small number of patients; therefore, the 
results observed when the MRI outcomes were analyzed 
at that time point should be considered with caution.
The strengths of our study are that this was a multi-
center, observational study with randomized selection of 
patients at each site. As this was a real-life study, the re-
sults can be considered meaningful to everyday clinical 
practice.
In conclusion, after 12 months of treatment both FIN 
and NTZ reduced the ARR, but ARR percent reduction 
was significantly higher with NTZ although these differ-
ences were minimized, and the statistical significance was 
lost in the second and third year. More beneficial effect 
on radiologic activity was also obtained with NTZ during 
the first year of treatment. Treatment persistence was sig-
nificantly higher in patients receiving FIN. 
Head-to-head clinical studies comparing FIN versus 
NTZ are warranted to clarify the contradictory results 
found in published observational studies.
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